Kymera Therapeutics, Inc 10-Q for FY2026 Q3
Kymera Therapeutics, Inc. (KYMR)
10-Q
2026-10-29
For: 2026-09-30
View Original
Added on
October 29, 2026
About this 10-Q
Kymera Therapeutics, Inc filed this 10-Q on October 29, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Kymera Therapeutics posted a $132.0 million net loss for the quarter ended September 30, 2026 as research and development expenses rose to $128.5 million from $74.1 million. Cash, cash equivalents and marketable securities were $1,646 million, expected to fund operations into 2029. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $0
- compared with $2.76M a year earlier
- Net loss
- $132M
- compared with a net loss of $82.18M a year earlier
- Diluted EPS
- -$1.32
- compared with -$0.94 a year earlier